233 related articles for article (PubMed ID: 32809070)
1. Real-world adherence, persistence, and in-class switching during use of dipeptidyl peptidase-4 inhibitors: a systematic review and meta-analysis involving 594,138 patients with type 2 diabetes.
Ogundipe O; Mazidi M; Chin KL; Gor D; McGovern A; Sahle BW; Jermendy G; Korhonen MJ; Appiah B; Ademi Z; De Bruin ML; Liew D; Ofori-Asenso R
Acta Diabetol; 2021 Jan; 58(1):39-46. PubMed ID: 32809070
[TBL] [Abstract][Full Text] [Related]
2. Dynamics of switching, adherence, and persistence of dipeptidyl peptidase-4 inhibitors use: A nationwide cohort study.
Ofori-Asenso R; Ilomaki J; Chin KL; Mazidi M; Zomer E; Bell JS; Magliano DJ; Liew D
Diabetes Res Clin Pract; 2019 Dec; 158():107909. PubMed ID: 31697992
[TBL] [Abstract][Full Text] [Related]
3. Adherence and Persistence with DPP-4 Inhibitors Versus Pioglitazone in Type 2 Diabetes Patients with Chronic Kidney Disease: A Retrospective Claims Database Analysis.
Gor D; Lee TA; Schumock GT; Walton SM; Gerber BS; Nutescu EA; Touchette DR
J Manag Care Spec Pharm; 2020 Jan; 26(1):67-75. PubMed ID: 31880221
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis of studies examining medication adherence, persistence, and discontinuation of oral antihyperglycemic agents in type 2 diabetes.
Iglay K; Cartier SE; Rosen VM; Zarotsky V; Rajpathak SN; Radican L; Tunceli K
Curr Med Res Opin; 2015; 31(7):1283-96. PubMed ID: 26023805
[TBL] [Abstract][Full Text] [Related]
5. Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus.
Farr AM; Sheehan JJ; Curkendall SM; Smith DM; Johnston SS; Kalsekar I
Adv Ther; 2014 Dec; 31(12):1287-305. PubMed ID: 25504156
[TBL] [Abstract][Full Text] [Related]
6. Adherence, Persistence, and Switching Among People Prescribed Sodium Glucose Co-transporter 2 Inhibitors: A Nationwide Retrospective Cohort Study.
Ofori-Asenso R; Liew D; Lalic S; Mazidi M; Magliano DJ; Ademi Z; Bell JS; Ilomaki J
Adv Ther; 2019 Nov; 36(11):3265-3278. PubMed ID: 31482509
[TBL] [Abstract][Full Text] [Related]
7. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.
Min SH; Yoon JH; Hahn S; Cho YM
Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155214
[TBL] [Abstract][Full Text] [Related]
8. Adherence and persistence in patients with type 2 diabetes mellitus newly initiating canagliflozin, dapagliflozin, dpp-4s, or glp-1s in the United States.
Cai J; Divino V; Burudpakdee C
Curr Med Res Opin; 2017 Jul; 33(7):1317-1328. PubMed ID: 28418262
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials.
Ling J; Cheng P; Ge L; Zhang DH; Shi AC; Tian JH; Chen YJ; Li XX; Zhang JY; Yang KH
Acta Diabetol; 2019 Mar; 56(3):249-272. PubMed ID: 30242726
[TBL] [Abstract][Full Text] [Related]
10. Comparison of medication adherence and persistence in type 2 diabetes: A systematic review and meta-analysis.
McGovern A; Tippu Z; Hinton W; Munro N; Whyte M; de Lusignan S
Diabetes Obes Metab; 2018 Apr; 20(4):1040-1043. PubMed ID: 29135080
[TBL] [Abstract][Full Text] [Related]
11. Adherence to dipeptidyl peptidase-4 inhibitor therapy among type 2 diabetes patients with employer-sponsored health insurance in Japan.
Kurtyka K; Nishikino R; Ito C; Brodovicz K; Chen Y; Tunceli K
J Diabetes Investig; 2016 Sep; 7(5):737-43. PubMed ID: 27182033
[TBL] [Abstract][Full Text] [Related]
12. Heart failure hospitalization risk associated with use of two classes of oral antidiabetic medications: an observational, real-world analysis.
Gautam S; Agiro A; Barron J; Power T; Weisman H; White J
Cardiovasc Diabetol; 2017 Jul; 16(1):93. PubMed ID: 28756774
[TBL] [Abstract][Full Text] [Related]
13. DPP4 Inhibitors in the Management of Hospitalized Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Rabizadeh S; Tavakoli Ardakani MA; Mouodi M; Bitaraf M; Shab-Bidar S; Esteghamati A; Nakhjavani M
Adv Ther; 2020 Sep; 37(9):3660-3675. PubMed ID: 32671686
[TBL] [Abstract][Full Text] [Related]
14. The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials.
Yang J; Huang C; Wu S; Xu Y; Cai T; Chai S; Yang Z; Sun F; Zhan S
PLoS One; 2017; 12(12):e0187537. PubMed ID: 29206832
[TBL] [Abstract][Full Text] [Related]
15. Poor adherence and persistence to sodium glucose co-transporter 2 inhibitors in real-world settings: Evidence from a systematic review and meta-analysis.
Ofori-Asenso R; Sahle BW; Chin KL; Mazidi M; Ademi Z; De Bruin ML; Liew D
Diabetes Metab Res Rev; 2021 Jan; 37(1):e3350. PubMed ID: 32447808
[TBL] [Abstract][Full Text] [Related]
16. Adherence, persistence, and treatment discontinuation with sitagliptin compared with sulfonylureas as add-ons to metformin: A retrospective cohort database study.
Bloomgarden ZT; Tunceli K; Liu J; Brodovicz KG; Mavros P; Engel SS; Radican L; Chen Y; Rajpathak S; Qiu Y; Brudi P; Fonseca V
J Diabetes; 2017 Jul; 9(7):677-688. PubMed ID: 27531167
[TBL] [Abstract][Full Text] [Related]
17. Concordance with prescribing information dosage recommendations for dipeptidyl-peptidase-4 inhibitors among type 2 diabetes mellitus patients with moderate to severe chronic kidney disease.
Huang H; Shetty S; Bauer E; Lang K
Curr Med Res Opin; 2018 Jun; 34(6):1021-1027. PubMed ID: 29231750
[TBL] [Abstract][Full Text] [Related]
18. Effect of dipeptidyl peptidase-4 inhibitors on postprandial glucagon level in patients with type 2 diabetes mellitus: A systemic review and meta-analysis.
Chai S; Zhang R; Zhang Y; Carr RD; Zheng Y; Rajpathak S; Ji L
Front Endocrinol (Lausanne); 2022; 13():994944. PubMed ID: 36313782
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of combination therapy with an α-glucosidase inhibitor and a dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: A systematic review with meta-analysis.
Min SH; Yoon JH; Hahn S; Cho YM
J Diabetes Investig; 2018 Jul; 9(4):893-902. PubMed ID: 28950431
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.
Amori RE; Lau J; Pittas AG
JAMA; 2007 Jul; 298(2):194-206. PubMed ID: 17622601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
